Karyopharm Therapeutics Inc. Sustainability Profile
Karyopharm Therapeutics Inc., a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2010, Karyopharm has made significant strides in the industry, particularly with its flagship product, XPOVIO (selinexor), which targets the nuclear export protein XPO1 to enhance cancer treatment efficacy. With a strong presence in the oncology sector, Karyopharm is dedicated to addressing unmet medical needs through its unique approach to drug development. The company has achieved notable milestones, including regulatory approvals and partnerships that bolster its market position. Karyopharm's commitment to advancing therapeutic options underscores its role as a key player in the biopharmaceutical landscape, striving to improve patient outcomes globally.
DitchCarbon Score
How does Karyopharm Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Karyopharm Therapeutics Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Karyopharm Therapeutics Inc.'s reported carbon emissions
Karyopharm Therapeutics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Karyopharm has not inherited any emissions data from a parent or related organization, indicating that their climate commitments and emissions reporting are independent. Without available data or established targets, it is unclear how Karyopharm is addressing climate change or its carbon footprint within the biopharmaceutical industry context. In summary, Karyopharm Therapeutics Inc. has yet to disclose any emissions data or climate commitments, leaving a gap in their environmental accountability.
How Carbon Intensive is Karyopharm Therapeutics Inc.'s Industry?
How Carbon Intensive is Karyopharm Therapeutics Inc.'s Location?
Karyopharm Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Karyopharm Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
